Trials / Completed
CompletedNCT00723216
Japanese Efficacy and Safety Study of Enoxaparin in Patients With Curative Abdominal Cancer Surgery
Multicenter, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Enoxaparin Sodium (RP54563) 20mg Bid for 14 Days for Prevention of Venous Thromboembolism in Patients With Curative Abdominal Cancer Surgery. Physical Prophylaxis Only Arm [Intermittent Pneumatic Compression (IPC)] Will be Used as an Indicator of Event Rates.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 151 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the effects of enoxaparin on venous thromboembolism incidence and bleeding rate (major and minor bleeding) in patients undergoing curative abdominal cancer surgery. The secondary objective is evaluate the incidence of adverse events of enoxaparin in these patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | enoxaparin | 20 mg twice a day |
| OTHER | Physical prophylaxis |
Timeline
- Start date
- 2007-03-01
- Primary completion
- 2007-12-01
- Completion
- 2007-12-01
- First posted
- 2008-07-28
- Last updated
- 2010-04-05
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT00723216. Inclusion in this directory is not an endorsement.